{
    "clinical_study": {
        "@rank": "43397", 
        "arm_group": {
            "arm_group_label": "E2Nomac combined oral contraceptive", 
            "arm_group_type": "Experimental", 
            "description": "Women with demonstrated HMB at baseline will be assigned to 3 cycles of a 24/4 day E2Nomac combined pill."
        }, 
        "brief_summary": {
            "textblock": "Women with measured menstrual bleeding >80ml per cycle and no contraindications to combined\n      oral contraceptive use will be assigned to an oestradiol/nomegestrol acetate oral\n      contraceptive for 3 cycles during which they will collect all menstrual blood and send all\n      used sanitary protection to the laboratory at the University of Sydney for estimation of\n      blood loss by the alkaline haematin method.\n\n      Hypothesis:\n\n      An E2/NOMAC combined pill will be effective in controlling HMB in the majority of women\n      without structural pelvic pathology.\n\n      Main outcome:\n\n      The primary efficacy end-point will be the proportion of women with a reduction of menstrual\n      blood loss \u2265 50% from baseline."
        }, 
        "brief_title": "A New Treatment Option for Heavy Menstrual Bleeding", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Menorrhagia", 
        "condition_browse": {
            "mesh_term": [
                "Hemorrhage", 
                "Menorrhagia"
            ]
        }, 
        "detailed_description": {
            "textblock": "Women will collect menstrual blood for 3 cycles and will be eligible to enter the treatment\n      phase if in two of the three pre-treatment cycles the measured menstrual blood loss (MBL)is\n      >80ml. The mean of these baseline MBL measurements will be the comparator for the efficacy\n      treatment measurement. Iron studies (serum ferritin, Fe and transferrin) will also be\n      measured pre and post treatment and related to women's assessment of their quality of life\n      measured on a validated questionnaire."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Women aged 18-50 years having regular menstrual cycles\n\n          -  Women willing to collect all sanitary protection for 6 cycles\n\n          -  Women with no contraindications to use of combined hormonal contraception\n\n          -  Women not using  any hormonal contraception or any treatment for HMB\n\n          -  Women who have no demonstrable uterine pathology on pelvic ultrasound\n\n          -  Women who have demonstrated a MBL >80mls in 2 of 3 menstrual periods during the\n             pre-treatment phase will be eligible to enter the treatment phase\n\n        Exclusion Criteria:\n\n          -  Women for whom combined oral contraceptives are contraindicated\n\n          -  Women unwilling to collect all sanitary protection for 6 cycles\n\n          -  Women using hormonal  contraception or any treatment for HMB\n\n          -  Women who have demonstrable uterine pathology on pelvic ultrasound\n\n          -  Women who have demonstrated a MBL \u226480mls in 2 of 3 consecutive menstrual periods"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "50 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 23, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01715025", 
            "org_study_id": "R2012-7"
        }, 
        "intervention": {
            "arm_group_label": "E2Nomac combined oral contraceptive", 
            "description": "Women will start the first cycle of the COC on the first day of their period in the treatment phase of the study", 
            "intervention_name": "E2Nomac combined oral contraceptive", 
            "intervention_type": "Drug", 
            "other_name": "Zoely"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Contraceptive Agents", 
                "Contraceptives, Oral", 
                "Contraceptives, Oral, Combined"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "measured", 
            "heavy menstrual bleeding", 
            "combined oral contraceptive", 
            "alkaline haematin method"
        ], 
        "lastchanged_date": "October 29, 2012", 
        "location": {
            "facility": {
                "address": {
                    "city": "Sydney", 
                    "country": "Australia", 
                    "state": "New South Wales", 
                    "zip": "2131"
                }, 
                "name": "SCRHR"
            }, 
            "investigator": {
                "last_name": "Edith Weisberg, MB BS MM", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Australia"
        }, 
        "number_of_arms": "1", 
        "official_title": "An Open-labeled Pilot Study to Determine the Efficacy of an E2//Nomegestrol Acetate (E2/NOMAC)Combination Oral Contraceptive (COC) in the Management of Heavy Menstrual Bleeding (HMB)", 
        "overall_contact": {
            "email": "edithw@fpnsw.org.au", 
            "last_name": "Edith Weisberg, MB BS MM", 
            "phone": "61 2 8752 4342"
        }, 
        "overall_contact_backup": {
            "email": "janeh@fpnsw.org.au", 
            "last_name": "Jane Hangan, RN", 
            "phone": "61 409 091 511"
        }, 
        "overall_official": {
            "affiliation": "Sydney Centre for Reproductive Health Research FPNSW", 
            "last_name": "Edith Weisberg, MB BS MM", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Australia: National Health and Medical Research Council", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "A single arm open label intervention study", 
            "measure": "\u2022 The primary efficacy end-point will be the proportion of women with a reduction \u2265 50% from baseline", 
            "safety_issue": "No", 
            "time_frame": "Baseline to outcome 12weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01715025"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Open label single group measuring the efficacy of a combined hormonal contraceptive to restore a normal level of MBL", 
            "measure": "\u2022\u2022 A secondary efficacy endpoint will be the number and proportion of cycles with a normal blood loss \u2264 80mls", 
            "safety_issue": "No", 
            "time_frame": "\u2022Baseline to endpoint 12 weeks"
        }, 
        "source": "Sydney Centre for Reproductive Health Research", 
        "sponsors": {
            "collaborator": {
                "agency": "Merck Sharp & Dohme Corp.", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Sydney Centre for Reproductive Health Research", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2012"
    }
}